Cyclopharm (CYC.AX) Akcie Kurz
Cyclopharm Kurz
Tržby rostly o 6,2 % ročně za posledních 19 let na 32,33 Mil. AUD. Zisk na akcii klesal o 14,1 % ročně za posledních 10 let. čistá marže společnosti Cyclopharm je nyní -53,3 %, dolů z -28,5 % před několika lety. Cyclopharm aktuálně nabízí dividendový výnos kolem 2,27 %. Dividenda rostla o 4,4 % ročně za posledních 8 let. Medián cílové ceny analytiků je 1,53 AUD, tedy nad aktuální cenu o 247,7 %. Z 5 analytiků jich 4 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Cyclopharm
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Cyclopharm a analýza akcií
Nejčastější otázky týkající se akcie Cyclopharm
The business model of Cyclopharm Ltd revolves around the development and commercialization of nuclear medicine products. Cyclopharm is a global leader in the manufacture and distribution of Technegas, a diagnostic imaging agent used for the detection of pulmonary embolism. With a focus on nuclear medicine, Cyclopharm carries out research, development, and production activities to offer innovative solutions for physicians and patients in need of accurate diagnoses. By leveraging their expertise in nuclear medicine, Cyclopharm aims to improve medical imaging techniques and contribute to better patient outcomes worldwide.
Cyclopharm Ltd is primarily active in the medical and healthcare industries.
The main competitors of Cyclopharm Ltd in the market include Progenics Pharmaceuticals, Curium, and Navidea Biopharmaceuticals. These companies also operate in the medical imaging industry and offer products and services that compete with Cyclopharm's offerings.
Cyclopharm Ltd is a leading global radiopharmaceutical company. Established in 1988, Cyclopharm focuses on developing and commercializing innovative nuclear medicine products. The company specializes in technetium generators, used for diagnostic imaging procedures, particularly in lung ventilation and perfusion examinations. With a strong commitment to research and development, Cyclopharm has continued to expand its product portfolio and global presence over the years. The company is headquartered in Sydney, Australia, and has a strong track record in delivering advanced solutions for the medical imaging industry. Cyclopharm Ltd has emerged as a trusted name in the field of radiopharmaceuticals, providing cutting-edge diagnostic tools for better patient care.
Cyclopharm Ltd, a leading healthcare company, has achieved several significant milestones throughout its journey. The company has successfully developed and launched innovative nuclear medicine technologies, including Technegas, a ventilation imaging agent rapidly adopted by the global medical community. Cyclopharm Ltd has established a strong international presence, with distribution networks spanning across multiple continents, allowing them to provide their life-saving products to patients worldwide. The company's commitment to research and development has yielded groundbreaking advancements in diagnostic imaging, revolutionizing the industry. Cyclopharm Ltd continues to strive for excellence, consistently delivering cutting-edge solutions and improving patient outcomes.
Cyclopharm Ltd is primarily present in Australia, New Zealand, and Canada.
Cyclopharm Ltd represents values of innovation, excellence, and patient care. The company maintains a strong corporate philosophy centered around enhancing the field of nuclear medicine through advanced radiopharmaceutical products and services. Cyclopharm Ltd is committed to delivering reliable diagnostic solutions that enable healthcare professionals to effectively diagnose and monitor various diseases. With a focus on research and development, the company strives to introduce groundbreaking technologies and therapies to improve patient outcomes. As a leader in the nuclear medicine industry, Cyclopharm Ltd continuously aims to provide cutting-edge solutions that contribute to the advancement of medical imaging and patient well-being.
Analytici aktuálně stanovují průměrnou cílovou cenu 1,53 AUD pro akcii Cyclopharm (medián: 1,53 AUD), tedy +247,7 % vůči poslední ceně. Konsensus vychází z 5 hodnocení analytiků.
5 analytiků aktuálně hodnotí akcii Cyclopharm: 4 doporučuje koupit, 1 držet a 0 prodat. Pro rok 2026 analytici očekávají u Cyclopharm tržby 37,20 Mil. AUD a zisk na akcii -0,13 AUD.
Při aktuálním kurzu se akcie Cyclopharm obchoduje za 0,27 EUR (0,44 AUD).
Cyclopharm Ltd is an Australian medical technology company specializing in X-ray diagnostics. The company offers innovative diagnostic solutions and services for nuclear medicine imaging and therapy planning. The company's main business model focuses on three different divisions: diagnostics, therapy planning, and research. Each division has its own products and services. For diagnostics, Cyclopharm offers Atomlab® Systems, a platform for nuclear medicine imaging that combines PET and SPECT technology. Atomlab® Systems facilitates radiologists and doctors in making critical decisions by providing detailed images of the body to help detect abnormalities and diseases. For therapy planning, Cyclopharm offers Technegas®, a technology that allows for checking lung function and perfusion to support the diagnosis of diseases such as pulmonary embolism. Technegas® is approved by the European Union and the US Food and Drug Administration (FDA) and is considered an important part of clinical practice. In addition, Cyclopharm offers a comprehensive portfolio of radioactive isotopes used in diagnostics and therapy planning. Cyclopharm's research division focuses on developing new diagnostic methods and technologies to improve nuclear medicine imaging and deliver better outcomes for patients. The company collaborates with leading academic institutions and research facilities worldwide to develop innovative diagnostic and treatment options. Cyclopharm is headquartered in Sydney, Australia, and distributes its products and services globally. The company employs approximately 100 employees and is listed on the Australian stock exchange. Cyclopharm's business model is based on offering innovative and high-quality diagnostic solutions tailored to the needs of radiologists, doctors, and patients. By combining PET and SPECT technology, Technegas technology, and an isotope portfolio, Cyclopharm has a unique position in nuclear medicine imaging. The company is also committed to sustainability and strives for environmental compatibility and safety in all aspects of its products and services. It works closely with regulatory authorities to ensure compliance with all relevant regulations and guidelines. Overall, Cyclopharm is a leading provider of diagnostic solutions and services in nuclear medicine imaging. Through innovative technology and a strong focus on research and development, the company will continue to play an important role in the industry and contribute to improving healthcare worldwide.
Tržby očekávané za Cyclopharm činí 37,20 Mil. AUD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Cyclopharm činí -14,20 Mil. AUD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Cyclopharm je aktuálně -3,41. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Cyclopharm.
Poměr ceny k tržbám (P/S) Cyclopharm je aktuálně 1,30. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Cyclopharm.
Score kvality pro Cyclopharm je 5/10.
ISIN Cyclopharm je AU000000CYC5. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
Ticker Cyclopharm je CYC.AX. Symbol tickeru se používá k obchodování akcií Cyclopharm na burze.
Cyclopharm akcie
Cyclopharm Peer Group
Cyclopharm FIGI
Všechny fundamentální údaje o Cyclopharm v podrobné analýze
Naše analýzy akcií společnosti Cyclopharm zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Cyclopharm. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: